lutetium-177

The authors call the radioligand approach hormone therapy sparing.

Outside this study, one community practice, Associates in Radiation Medicine, told Aunt Minnie it is targeting its first lutetium-177 injection for the first quarter of 2027.

Some men on LU-177 PSMA therapy also need radiation to the spine, sometimes within weeks of a dose.

Memorial Sloan Kettering looked back at 54 of them, heavily pretreated, who had spine radiation within six months of the radioligand.

Over a median follow-up of about four months, there were no grade three or worse spine complications.

So it suggests that if you pick patients not with only 95% loss, but maybe even 99% or 100% loss, that you're going to select populations that are more likely to benefit from capivacertib or CAPI.

And everyone's giving LU-177 therapy in the setting of CRPC.

It's approved both pre- and post-chemo based on PSMA-4 and vision.

PSMA edition was presented last year This is a metastatic HSPC study.

You had to have a PSMA-positive lesion, which the majority of these patients do.

And they randomized patients to ADT plus an ARPI with or without LU-177.

And you can see that, basically, they all got six cycles.

And they all tolerated this relatively well, although...